Improvement in dermatomyositis-associated muscle disease with anifrolumab.
作者信息
Shayegan Leila H, Shaw Katharina S, Wieschhoff Ged G, Ezeh Nnenna, Kim Yoo Jung, Shahriari Neda, Anshelevich Ellen E, Acevedo Lorena A, LaChance Avery, Dedeoglu Fatma, Castillo Rochelle L, Ho Allen W, Vleugels Ruth Ann
机构信息
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Dermatology Program, Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
出版信息
Br J Dermatol. 2025 May 19;192(6):1126-1128. doi: 10.1093/bjd/ljaf064.
Abstract
摘要
相似文献
1
Improvement in dermatomyositis-associated muscle disease with anifrolumab.阿尼芬净治疗皮肌炎相关肌肉疾病的疗效改善。
Br J Dermatol. 2025 May 19;192(6):1126-1128. doi: 10.1093/bjd/ljaf064.
2
A Novel Treatment for Skin Manifestations in Dermatomyositis: A Case Report.皮肌炎皮肤表现的一种新治疗方法：病例报告
Cureus. 2024 Aug 12;16(8):e66704. doi: 10.7759/cureus.66704. eCollection 2024 Aug.
3
Anifrolumab in Refractory Dermatomyositis and Antisynthetase Syndrome.阿尼鲁单抗治疗难治性皮肌炎和抗合成酶综合征
Case Rep Rheumatol. 2025 Apr 21;2025:5560523. doi: 10.1155/crrh/5560523. eCollection 2025.
4
Recalcitrant Dermatomyositis Treated With Anifrolumab.用阿尼鲁单抗治疗难治性皮肌炎。
ACR Open Rheumatol. 2025 Jan;7(1):e11792. doi: 10.1002/acr2.11792.
5
Rapid Improvement in Recalcitrant Cutaneous Juvenile Dermatomyositis With Anifrolumab Treatment.阿尼芬净治疗难治性皮肤型青少年皮肌炎疗效显著
JAMA Dermatol. 2024 Feb 1;160(2):237-238. doi: 10.1001/jamadermatol.2023.4744.
6
A novel treatment for refractory dermatomyositis: A systematic review of anifrolumab and dermatomyositis.难治性皮肌炎的一种新疗法：阿尼鲁单抗与皮肌炎的系统评价
J Am Acad Dermatol. 2025 Aug;93(2):543-546. doi: 10.1016/j.jaad.2025.04.025. Epub 2025 Apr 12.
7
[Translated article] Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses.[翻译文章] 阿尼鲁单抗在系统性红斑狼疮、皮肤型红斑狼疮及其他自身免疫性皮肤病中的应用
Actas Dermosifiliogr. 2025 Jan;116(1):T55-T67. doi: 10.1016/j.ad.2024.10.008. Epub 2024 Oct 9.
8
Successful Treatment of Refractory Cutaneous Dermatomyositis With Anifrolumab.用阿尼鲁单抗成功治疗难治性皮肤型皮肌炎
Int J Dermatol. 2025 Feb 10. doi: 10.1111/ijd.17675.
9
Refractory dermatomyositis responsive to anifrolumab.对阿尼鲁单抗有反应的难治性皮肌炎
JAAD Case Rep. 2023 Nov 7;43:27-29. doi: 10.1016/j.jdcr.2023.10.023. eCollection 2024 Jan.
10
Anifrolumab in recalcitrant cutaneous dermatomyositis: A multicenter retrospective cohort study.阿尼鲁单抗治疗难治性皮肤型皮肌炎：一项多中心回顾性队列研究。
J Am Acad Dermatol. 2024 Dec;91(6):1217-1219. doi: 10.1016/j.jaad.2024.07.1491. Epub 2024 Aug 12.
引用本文的文献
1
Disease Activity-Dependent Siglec-1 Expression on Monocyte Subsets of Patients with Idiopathic Inflammatory Myopathies.特发性炎性肌病患者单核细胞亚群上疾病活动依赖性唾液酸结合免疫球蛋白样凝集素-1表达
Int J Mol Sci. 2025 May 21;26(10):4950. doi: 10.3390/ijms26104950.
本文引用的文献
1
A Novel Treatment for Skin Manifestations in Dermatomyositis: A Case Report.皮肌炎皮肤表现的一种新治疗方法：病例报告
Cureus. 2024 Aug 12;16(8):e66704. doi: 10.7759/cureus.66704. eCollection 2024 Aug.
2
Anifrolumab in recalcitrant cutaneous dermatomyositis: A multicenter retrospective cohort study.阿尼鲁单抗治疗难治性皮肤型皮肌炎：一项多中心回顾性队列研究。
J Am Acad Dermatol. 2024 Dec;91(6):1217-1219. doi: 10.1016/j.jaad.2024.07.1491. Epub 2024 Aug 12.
3
Elevated type I IFN signalling directly affects CD8 T-cell distribution and autoantigen recognition of the skeletal muscles in active JDM patients.活性 JDM 患者中 I 型干扰素信号的上调直接影响 CD8 T 细胞在骨骼肌中的分布和自身抗原识别。
J Autoimmun. 2024 Jun;146:103232. doi: 10.1016/j.jaut.2024.103232. Epub 2024 Apr 30.
4
Refractory dermatomyositis responsive to anifrolumab.对阿尼鲁单抗有反应的难治性皮肌炎
JAAD Case Rep. 2023 Nov 7;43:27-29. doi: 10.1016/j.jdcr.2023.10.023. eCollection 2024 Jan.
5
Rapid Improvement in Recalcitrant Cutaneous Juvenile Dermatomyositis With Anifrolumab Treatment.阿尼芬净治疗难治性皮肤型青少年皮肌炎疗效显著
JAMA Dermatol. 2024 Feb 1;160(2):237-238. doi: 10.1001/jamadermatol.2023.4744.
6
Dermatomyositis and type 1 interferons.皮肌炎与 1 型干扰素。
Curr Rheumatol Rep. 2010 Jun;12(3):198-203. doi: 10.1007/s11926-010-0101-6.
Zotero 插件